The University of Southampton
University of Southampton Institutional Repository

Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases

Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases
Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases
With regard to inflammatory processes, the main fatty acids of interest are the n-6 PUFA arachidonic acid (AA), which is the precursor of inflammatory eicosanoids like prostaglandin E(2) and leukotriene B(4), and the n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA are found in oily fish and fish oils. EPA and DHA inhibit AA metabolism to inflammatory eicosanoids. They also give rise to mediators that are less inflammatory than those produced from AA or that are anti-inflammatory. In addition to modifying the lipid mediator profile, n-3 PUFAs exert effects on other aspects of inflammation like leukocyte chemotaxis and inflammatory cytokine production. Some of these effects are likely due to changes in gene expression, as a result of altered transcription factor activity. Fish oil has been shown to decrease colonic damage and inflammation, weight loss and mortality in animal models of colitis. Fish oil supplementation in patients with inflammatory bowel diseases results in n-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles. Clinical outcomes have been variably affected by fish oil, although some trials report improved gut histology, decreased disease activity, use of corticosteroids and relapse
fatty acids, administration & dosage, pharmacology, therapeutic use, etiology, fish-oil, mortality, biosynthesis, arachidonic-acid, chemistry, animal, outcomes, arachidonic acid, gene-expression, activity, nutrition, fatty acid, omega-3, genetics, fish oil, weight, review, physiology, fish oils, clinical trials as topic, metabolism, eicosapentaenoic acid, disease-activity, humans, cytokines, terminology as topic, drug therapy, report, disease, ppar gamma, acid, trial, disease models, gene expression, animals, unsaturated, inflammatory bowel diseases, docosahexaenoic acid, antagonists & inhibitors, inflammation mediators, eicosanoids, gene expression regulation, inflammation, pufa, expression, human, nf-kappa b
885-897
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6

Calder, Philip C. (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Molecular Nutrition & Food Research, 52 (8), 885-897. (doi:10.1002/mnfr.200700289).

Record type: Article

Abstract

With regard to inflammatory processes, the main fatty acids of interest are the n-6 PUFA arachidonic acid (AA), which is the precursor of inflammatory eicosanoids like prostaglandin E(2) and leukotriene B(4), and the n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA are found in oily fish and fish oils. EPA and DHA inhibit AA metabolism to inflammatory eicosanoids. They also give rise to mediators that are less inflammatory than those produced from AA or that are anti-inflammatory. In addition to modifying the lipid mediator profile, n-3 PUFAs exert effects on other aspects of inflammation like leukocyte chemotaxis and inflammatory cytokine production. Some of these effects are likely due to changes in gene expression, as a result of altered transcription factor activity. Fish oil has been shown to decrease colonic damage and inflammation, weight loss and mortality in animal models of colitis. Fish oil supplementation in patients with inflammatory bowel diseases results in n-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles. Clinical outcomes have been variably affected by fish oil, although some trials report improved gut histology, decreased disease activity, use of corticosteroids and relapse

Full text not available from this repository.

More information

Published date: 2008
Keywords: fatty acids, administration & dosage, pharmacology, therapeutic use, etiology, fish-oil, mortality, biosynthesis, arachidonic-acid, chemistry, animal, outcomes, arachidonic acid, gene-expression, activity, nutrition, fatty acid, omega-3, genetics, fish oil, weight, review, physiology, fish oils, clinical trials as topic, metabolism, eicosapentaenoic acid, disease-activity, humans, cytokines, terminology as topic, drug therapy, report, disease, ppar gamma, acid, trial, disease models, gene expression, animals, unsaturated, inflammatory bowel diseases, docosahexaenoic acid, antagonists & inhibitors, inflammation mediators, eicosanoids, gene expression regulation, inflammation, pufa, expression, human, nf-kappa b

Identifiers

Local EPrints ID: 70320
URI: https://eprints.soton.ac.uk/id/eprint/70320
PURE UUID: c69778c5-cae3-4847-a74a-634a42ff188d

Catalogue record

Date deposited: 02 Feb 2010
Last modified: 24 Jul 2018 16:31

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×